
Jaguar Health JAGX
$ 0.42
-3.03%
Annual report 2025
added 04-07-2026
Jaguar Health Interest Expense 2011-2026 | JAGX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Jaguar Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67 K | 231 K | 6.38 M | 12.7 M | 8.42 M | 2.79 M | 5.73 M | 2.63 M | 1.21 M | 986 K | 3.32 M | 345 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.7 M | 67 K | 3.74 M |
Quarterly Interest Expense Jaguar Health
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 K | -15 K | -56 K | -162 K | -108 K | 611 K | 500 K | 3.45 M | 2.18 M | - | 2.73 M | 2.54 M | 4.19 M | - | 2.08 M | 2.01 M | 1.9 M | - | 581 K | 479 K | 199 K | - | 1.35 M | 3.66 M | 547 K | - | 872 K | 712 K | 602 K | - | 465 K | 156 K | 180 K | - | 235 K | 255 K | 284 K | - | 164 K | 1.94 M | 933 K | - | 148 K | 7.01 K | 13.2 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.19 M | -162 K | 990 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.88 | 3.89 % | $ 9.34 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
5.2 M | $ 323.44 | -2.98 % | $ 42.4 B | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Aligos Therapeutics
ALGS
|
2.2 M | $ 7.93 | 6.81 % | $ 78.4 M | ||
|
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | ||
|
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 21.93 | 1.15 % | $ 1.03 B | ||
|
Cabaletta Bio
CABA
|
2 M | $ 3.54 | 4.12 % | $ 356 M | ||
|
CymaBay Therapeutics
CBAY
|
18.9 M | - | - | $ 3.45 B | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 101.62 | 2.16 % | $ 27.2 B | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 3.07 | -3.15 % | $ 5.05 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
-4.81 M | - | -5.16 % | $ 5.39 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
58 K | $ 1.38 | -10.97 % | $ 355 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.22 | -0.59 % | $ 451 M | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 23.83 | -3.05 % | $ 3.03 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.54 | 3.02 % | $ 410 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-257 K | - | -16.75 % | $ 25.8 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 33.61 | -0.77 % | $ 2.23 B | ||
|
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | ||
|
CNS Pharmaceuticals
CNSP
|
7.03 K | $ 2.72 | -1.09 % | $ 1.21 M |